6 completed, 2 recruiting, 1 available, 1 not yet recruiting. 8 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow tideglusib: new trials by email Literature Review of tideglusib trials Research Report on tideglusib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis Tideglusib - Amyotrophic Lateral Sclerosis | Phase 2 | Not yet recruiting | University of Zurich | 98 | 2025-12-01 | 2025-01-28 |
| Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy Tideglusib, Placebo - Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy | Phase 2 | Recruiting | Hamilton Health Sciences Corporation | 120 | 2025-03-21 | 2026-03-12 |
| Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy Tideglusib - Congenital Myotonic Dystrophy | Phase 2 / Phase 3 | Recruiting | AMO Pharma Limited | 76 | 2021-08-23 | 2025-05-28 |
| Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy Tideglusib, Placebo - Congenital Myotonic Dystrophy | Phase 2 / Phase 3 | Completed | AMO Pharma Limited | 56 | 2021-03-03 | 2025-10-08 |
| Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Tideglusib - Myotonic Dystrophy 1 | Phase 2 | Completed | AMO Pharma Limited | 16 | 2016-07-20 | 2025-09-11 |
| Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders Tideglusib, Placebo - Autism Spectrum Disorders | Phase 2 | Completed | Holland Bloorview Kids Rehabilitation Hospital | 83 | 2016-02-10 | 2025-07-16 |
| Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients tideglusib, Placebo - Alzheimer's Disease | Phase 2 | Completed | Noscira SA | 306 | 2011-04-01 | 2012-10-02 |
| Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy tideglusib, placebo - Progressive Supranuclear Palsy | Not applicable | Completed | Noscira SA | 146 | 2009-12-01 | 2012-01-05 |
| Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease NP031112, Placebo - Alzheimer´s Disease | Phase 1 / Phase 2 | Completed | Noscira SA | 30 | 2008-12-01 | 2009-11-11 |
| Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy Tideglusib - Congenital Myotonic Dystrophy | Available | AMO Pharma Limited | 2025-08-13 |
Myotonic Dystrophy (4) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Arrhythmias, Cardiac (1) · Arrhythmogenic Right Ventricular Dysplasia (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Death, Sudden, Cardiac (1) · Supranuclear Palsy, Progressive (1)
AMO Pharma Limited (4) · Noscira SA (3) · Hamilton Health Sciences Corporation (1) · Holland Bloorview Kids Rehabilitation Hospital (1) · University of Zurich (1)
Canada (4) · United Kingdom (4) · Germany (3) · United States (3) · Australia (2) · New Zealand (2) · Spain (2) · Belgium (1) · Finland (1) · France (1) · Switzerland (1)
Evdokia Anagnostou, M.D. (1) · Grainne Gorman, MB BCh BAO LRCP&SI MRCP FRCP (1) · Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM (1) · Jason D Roberts, MD MAS (1) · Joseph P Horrigan, MD (1) · Klaus-Christian Steinwachs, MD (1) · Manfred Windisch, Ph.D. (1) · Robert Nicolson, M.D. (1) · Teodoro del Ser, PhD (1) · Terry Bennett, M.D. (1)
PMID 28436538, PMID 32942085, PMID 38825840
2016 (2)